Appl. No. 09/553,969 Amdt. dated February 9, 2009 Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1611

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Previously Presented) An extrudable fragmented biocompatible resorbable single phase aqueous colloid which is substantially free from a free aqueous phase, said single phase aqueous colloid being present in an applicator having an extrusion orifice, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, comprises a protein, has an equilibrium swell from 400% to 5000%, and has at least one characteristic selected from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm, and (b) an *in vivo* degradation time of less than one year.

- 2-18. (Canceled)
- 19. (Previously Presented) The single phase aqueous colloid of claim 1, having a subunit size when fully hydrated in the range from 0.01 mm to 5 mm.
  - 20. (Canceled)
- 21. (Previously Presented) The single phase aqueous colloid of claim 1, having an in vivo degradation time of less than one year.
  - 22-23. (Canceled)
- 24. (Previously Presented) The single phase aqueous colloid of claim 1, wherein the single phase aqueous colloid has a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and an *in vivo* degradation time of less than one year.

Amendment under 37 CFR Examining Group 1611

- 25. (Previously Presented) The single phase aqueous colloid of claim 1, said single phase aqueous colloid being at least partially hydrated with an aqueous medium comprising an active agent.
- 26. (Previously Presented) The single phase aqueous colloid of claim 25, wherein the active agent is a clotting agent.
- 27. (Previously Presented) The single phase aqueous colloid of claim 26, wherein the clotting agent is thrombin.
  - 28. (Canceled)
- 29. (Previously Presented) The single phase aqueous colloid of claim 27, wherein the protein comprises gelatin.
- 30. (Previously Presented) The single phase aqueous colloid of claim 27, wherein the single phase aqueous colloid comprises a polysaccharide.
- 31. (Currently Amended) The single phase aqueous colloid of claim 27, wherein the single phase aqueous colloid <u>further</u> comprises a non-biological polymer.
- 32. (Currently Amended) The single phase aqueous colloid of claim 27, wherein the single phase aqueous colloid <u>further</u> comprises a polysaccharide or a non-biological polymer, or both.
  - 33. (Canceled)
- 34. (Previously Presented) An extrudable fragmented biocompatible resorbable single phase aqueous colloid present in an applicator having an extrusion orifice, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, is not hydrated above its capacity to absorb water, has an equilibrium swell from 400% to 5000%, and comprises gelatin, the single phase aqueous colloid having at least one characteristic selected

Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1611

from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and (b) an *in vivo* degradation time of less than one year.

- 35. (Previously Presented) An extrudable fragmented biocompatible resorbable single phase aqueous colloid which is substantially free from a free aqueous phase, said single phase aqueous colloid being present in an applicator having an extrusion orifice, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, has an equilibrium swell from 400% to 5000%, and comprises a protein and a polysaccharide, the single phase aqueous colloid having at least one characteristic selected from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and (b) an *in vivo* degradation time of less than one year.
- 36. (Previously Presented) An extrudable fragmented biocompatible resorbable single phase aqueous colloid which is substantially free from a free aqueous phase, said single phase aqueous colloid being present in an applicator having an extrusion orifice, wherein the single phase aqueous colloid has been fragmented by mechanical disruption, has an equilibrium swell from 400% to 5000%, and comprises a protein and a non-biological polymer, the single phase aqueous colloid having at least one characteristic selected from the group consisting of (a) a subunit size when fully hydrated in the range from 0.01 mm to 5 mm and (b) an *in vivo* degradation time of less than one year.